PDF(Pubmed)
Abstract：
UNASSIGNED: Circulating levels of C1q/TNF-α-related protein 6 (CTRP6) is an adipokine that is involved in regulation of glucose and lipid metabolism, inflammation, and insulin sensitivity. However, the exact role of CTRP6 in metabolic processes remains unclear due to conflicting findings. To address current gap, we aimed to investigate the serum levels of CTRP6 in patients with coronary artery disease (CAD) and its association with inflammatory cytokines.
UNASSIGNED: In this case-control study, the serum levels of CTRP6, interlukin-6 (IL-6), tumor necrosis factor- α (TNF-α), adiponectin, and fasting insulin were measured using enzyme-linked immunosorbent assay (ELISA) kits in a total of 176 participants, consisting of 88 CAD patients and 88 control subjects. Additionally, various anthropometric and biochemical measurements were measured and compared between cases and controls.
UNASSIGNED: The present study found that serum levels of CTRP6 were significantly higher in the CAD group (561.3 ± 15.14) compared to the control group (429.3 ± 12.85, p < 0.001). After adjusting for age, sex, and body mass index (BMI), CTRP6 levels were found to be positively associated with the risk of CAD (p < 0.001). Correlation analysis in CAD subjects revealed a positive correlation between CTRP6 levels and BMI, systolic blood pressure (SBP), malondialdehyde (MDA), TNF-α, and IL-6, as well as a negative correlation with creatinine and total anti-oxidant capacity.
UNASSIGNED: The findings of this study provide novel evidence that elevated serum levels of CTRP6 are significantly associated with an increased risk of developing CAD. Moreover, our results indicate a correlation between CTRP6 and various risk factors for atherosclerosis.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s40200-024-01415-5.
UNASSIGNED: In this case-control study, the serum levels of CTRP6, interlukin-6 (IL-6), tumor necrosis factor- α (TNF-α), adiponectin, and fasting insulin were measured using enzyme-linked immunosorbent assay (ELISA) kits in a total of 176 participants, consisting of 88 CAD patients and 88 control subjects. Additionally, various anthropometric and biochemical measurements were measured and compared between cases and controls.
UNASSIGNED: The present study found that serum levels of CTRP6 were significantly higher in the CAD group (561.3 ± 15.14) compared to the control group (429.3 ± 12.85, p < 0.001). After adjusting for age, sex, and body mass index (BMI), CTRP6 levels were found to be positively associated with the risk of CAD (p < 0.001). Correlation analysis in CAD subjects revealed a positive correlation between CTRP6 levels and BMI, systolic blood pressure (SBP), malondialdehyde (MDA), TNF-α, and IL-6, as well as a negative correlation with creatinine and total anti-oxidant capacity.
UNASSIGNED: The findings of this study provide novel evidence that elevated serum levels of CTRP6 are significantly associated with an increased risk of developing CAD. Moreover, our results indicate a correlation between CTRP6 and various risk factors for atherosclerosis.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s40200-024-01415-5.
摘要：
■C1q/TNF-α相关蛋白6（CTRP6）的循环水平是一种参与调节葡萄糖和脂质代谢的脂肪因子，炎症,和胰岛素敏感性。然而,由于发现相互矛盾,CTRP6在代谢过程中的确切作用尚不清楚.为了解决当前的差距，我们旨在研究冠心病（CAD）患者血清CTRP6水平及其与炎性细胞因子的关系。
■在本病例对照研究中，血清CTRP6，IL-6，IL-6，肿瘤坏死因子-α（TNF-α），脂联素,和空腹胰岛素使用酶联免疫吸附测定（ELISA）试剂盒在总共176名参与者中进行测量，由88名CAD患者和88名对照受试者组成。此外,测量了各种人体测量和生化测量，并在病例和对照组之间进行了比较。
■本研究发现，与对照组（429.3±12.85，p<0.001）相比，CAD组的CTRP6血清水平明显更高（561.3±15.14）。在调整了年龄之后,性别,和体重指数（BMI），发现CTRP6水平与CAD的风险呈正相关(p<0.001)。CAD受试者的相关分析显示CTRP6水平与BMI呈正相关,收缩压（SBP），丙二醛（MDA），TNF-α,和IL-6，以及与肌酐和总抗氧化能力的负相关。
■这项研究的结果提供了新的证据，表明血清CTRP6水平升高与发生CAD的风险增加显著相关。此外，我们的结果表明CTRP6与动脉粥样硬化的各种危险因素之间存在相关性.
■在线版本包含补充材料，可在10.1007/s40200-024-01415-5获得。
■在本病例对照研究中，血清CTRP6，IL-6，IL-6，肿瘤坏死因子-α（TNF-α），脂联素,和空腹胰岛素使用酶联免疫吸附测定（ELISA）试剂盒在总共176名参与者中进行测量，由88名CAD患者和88名对照受试者组成。此外,测量了各种人体测量和生化测量，并在病例和对照组之间进行了比较。
■本研究发现，与对照组（429.3±12.85，p<0.001）相比，CAD组的CTRP6血清水平明显更高（561.3±15.14）。在调整了年龄之后,性别,和体重指数（BMI），发现CTRP6水平与CAD的风险呈正相关(p<0.001)。CAD受试者的相关分析显示CTRP6水平与BMI呈正相关,收缩压（SBP），丙二醛（MDA），TNF-α,和IL-6，以及与肌酐和总抗氧化能力的负相关。
■这项研究的结果提供了新的证据，表明血清CTRP6水平升高与发生CAD的风险增加显著相关。此外，我们的结果表明CTRP6与动脉粥样硬化的各种危险因素之间存在相关性.
■在线版本包含补充材料，可在10.1007/s40200-024-01415-5获得。
